HASPIN and breast cancer: Sangivamycin inhibits cellular kinases that are overexpressed in some cancer cells — most notably protein kinase C and histone H3 associated protein kinase — leading to apoptosis in pancreatic cancer cells, breast cancer MCF-AR cells, and primary effusion lymphoma cells.